DE19753383A1 - Use of abciximab to treat microcirculation disorders - Google Patents

Use of abciximab to treat microcirculation disorders

Info

Publication number
DE19753383A1
DE19753383A1 DE19753383A DE19753383A DE19753383A1 DE 19753383 A1 DE19753383 A1 DE 19753383A1 DE 19753383 A DE19753383 A DE 19753383A DE 19753383 A DE19753383 A DE 19753383A DE 19753383 A1 DE19753383 A1 DE 19753383A1
Authority
DE
Germany
Prior art keywords
abciximab
sepsis
microcirculation disorders
platelets
platelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19753383A
Other languages
German (de)
Inventor
Gundula Wiemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WIEMANN, GUNDULA, 45279 ESSEN, DE
Original Assignee
SCHWARZ RUEDIGER 70193 STUTTGART DE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCHWARZ RUEDIGER 70193 STUTTGART DE filed Critical SCHWARZ RUEDIGER 70193 STUTTGART DE
Priority to DE19753383A priority Critical patent/DE19753383A1/en
Priority to JP2000522947A priority patent/JP2001524534A/en
Priority to CA002312824A priority patent/CA2312824A1/en
Priority to EP98965225A priority patent/EP1035868A1/en
Priority to PCT/EP1998/007833 priority patent/WO1999027962A1/en
Publication of DE19753383A1 publication Critical patent/DE19753383A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to the use of fibrinogen receptor-antagonists for preventing disseminated intravascular coagulation (DIC) related to sepsis or systemic inflammatory response syndrome (SIRS) in humans.

Description

Die Erfindung betrifft die Verwendung von Abciximab zur Behandlung von Mikrozirkulationsstörungen in Folge von Sepsis oder SIRS.The invention relates to the use of abciximab for the treatment of microcirculation disorders in Episode of sepsis or SIRS.

Hierbei sind unter Abciximab Fab-Fragmente eines monoklonalen Antikörpers gegen den GPIIb/IIIa-Rezeptor von Thrombozyten zu verstehen.Abciximab includes Fab fragments of a monoclonal antibody against the Understand GPIIb / IIIa receptor of platelets.

Stand der TechnikState of the art

Es ist bereits aus der Produktmonographie des Präparates Reopro(tm), Fa. Beiersdorf-Lilly und Fa. Centocor, bekannt, Abciximab zusätzlich zur Anwendung von Heparin und Acetylsalicylsäure zur Vermeidung von ischämischen kardialen Komplikationen bei Hochrisiko-Patienten anzuwenden, bei denen eine perkutane transluminale Koronarangioplastie durchgeführt wird. Wegen der bei der Anwendung auftretenden erhöhten Blutungshäufigkeit soll die Anwendung auf Patienten mit einem hohen Risiko für akute koronare Thrombosen beschränkt sein und auch hier nur dann erfolgen, wenn die Patenten zumindest eines der folgenden Kriterien aufweisen:
Angina pectoris mit folgenden Kennzeichen:
It is already known from the product monograph of the preparation Reopro (tm) from Beiersdorf-Lilly and from Centocor to use abciximab in addition to the use of heparin and acetylsalicylic acid to avoid ischemic cardiac complications in high-risk patients in whom percutaneous transluminal Coronary angioplasty is performed. Because of the increased bleeding frequency that occurs during use, use should be restricted to patients at high risk for acute coronary thrombosis and should only be carried out here if the patents have at least one of the following criteria:
Angina pectoris with the following characteristics:

  • - Therapieresistente Angina im Ruhezustand mit ischämischen ST-Veränderungen- Therapy-resistant angina at rest with ischemic ST changes
  • - Therapieresistente wiederholt auftretende Angina mit ischämischen ST-Veränderungen- Therapy-resistant, recurrent angina with ischemic ST changes
  • - Therapieresistente Postinfarktangina mit ischämischen ST-Veränderungen innerhalb von 7 Tagen nach Myokardinfarkt.- Therapy-resistant post-infarct angina with ischemic ST changes within 7 days after Myocardial infarction.

Akuter transmuraler Myokardinfarkt nicht älter als 12 Stunden, der folgendes Vorgehen erfordert:
Acute transmural myocardial infarction not older than 12 hours, which requires the following:

  • - direkter interventioneller Eingriff- direct interventional intervention
  • - Maßnahme bei nicht erfolgreicher thrombolytischer Therapie.- Measure in the event of unsuccessful thrombolytic therapy.

Angiographisch definierte, das Gefäßvolumen einengende Läsionen des Koronarkreislaufs
Angiographically defined lesions of the coronary circulation constricting the vascular volume

  • - 2 Merkmale einer Läsion Typ B- 2 characteristics of a type B lesion
  • - 1 Merkmal einer Läsion Typ C- 1 characteristic of a type C lesion
  • - 1 Merkmal einer Läsion Typ B bei Frauen < 65 Jahren und/oder bei Vorliegen eines Diabetes mellitus.- 1 characteristic of a type B lesion in women <65 years and / or in the presence of diabetes mellitus.

Es ist fernerhin bekannt, daß der Antikörper 7E3, der eine Entwicklungsvorstufe zu Abciximab darstellt, anfänglich durch seine Fähigkeit charakterisiert war, an GP IIb/IIIa-Rezeptoren sowohl ruhender als auch aktivierter Thrombozyten zu binden. Diese Rezeptoren sind bei der Bindung von fibrinogen an Thrombozyten von wesentlicher Bedeutung, wobei die Bindung von Fibrinogen an Thrombozyten eine Schlüsselrolle bei der Thrombozytenaggregation spielt.It is also known that antibody 7E3, which is a precursor to abciximab, was initially characterized by its ability to both quiescent at GP IIb / IIIa receptors also bind activated platelets. These receptors are involved in the binding of fibrinogen Platelets are essential, with the binding of fibrinogen to platelets a Plays a key role in platelet aggregation.

Bei der bekannten Anwendung von Abciximab wird als Dosierung zunächst intravenös eine Bolusinjektion (0,25 mg/kg Körpergewicht) mit anschließender kontinuierlicher intravenöser Infusion mit 10 µg/min empfohlenIn the known use of abciximab, a dose is initially given intravenously Bolus injection (0.25 mg / kg body weight) followed by continuous intravenous infusion with 10 µg / min recommended

Beschreibung der Erfindung; VorteileDescription of the invention; advantages

Erfindungsgemäß wird vorgeschlagen, Abciximab zur Behandlung von Mikrozirkulationsstörungen in Folge von Sepsis oder SIRS zu verwenden.According to the invention it is proposed to use abciximab for the treatment of microcirculation disorders Episode of sepsis or SIRS to use.

Überraschenderweise zeigt Abciximab eine besonders hohe Wirksamkeit bei der Vermeidung von Mikrozirkulationsstörungen bzw. Verbesserung der Mikrozirkulation nach einem Auftreten von Mikrozirkulationsstörungen, wie sie infolge von Sepsis oder SIRS auftreten. Hiermit kann vorteilhafter Weise das Risiko eines Multiorganversagens vermindert werden.Surprisingly, abciximab is particularly effective in preventing Microcirculation disorders or improvement of the microcirculation after an occurrence of Microcirculation disorders, such as those resulting from sepsis or SIRS. This can be more advantageous Way the risk of multi-organ failure can be reduced.

Der vorgeschlagenen Verwendung liegt die Erkenntnis zugrunde, daß die sog. Endstrecke der Thrombozytenaktivierung durch die fibrinogenvermittelte Thrombozyten-Thrombozyten-Interaktion charakterisiert ist, welche nur durch eine Konformationsänderung des GP IIb/IIIa Komplexes auf der Oberfläche der Thrombozyten möglich wird, und dann eine Fibrinogenbindung zwischen 2 Fibrinogenrezeptoren zur Folge hat. Das symmetrische Fibrinogenmolekül überbrückt den Spalt zwischen den Glykoprotein-IIb/IIIa-Komplexen zweier benachbarter Thrombozyten. Mit Hilfe von In-vitro- Assays wurde gezeigt, daß c7E3 die GP IIb/IIIa abhängige Thrombozytenaggregation dosisabhängig hemmt , wobei diese Hemmung unabhängig davon ist,welcher Stimulus für die Plättchenaggregation wie z. B. ADP, Kollagen, Thrombin, Adrenalin etc. verwendet wurde.The proposed use is based on the knowledge that the so-called final section of the Platelet activation through fibrinogen-mediated platelet-platelet interaction is characterized, which only by a conformational change of the GP IIb / IIIa complex on the Platelet surface becomes possible, and then a fibrinogen bond between 2 Fibrinogen receptors. The symmetrical fibrinogen molecule bridges the gap between the glycoprotein IIb / IIIa complexes of two neighboring platelets. With the help of in vitro Assays have been shown that c7E3 is GP IIb / IIIa dependent platelet aggregation dose dependent inhibits, which inhibition is independent of which stimulus for platelet aggregation such as B. ADP, collagen, thrombin, adrenaline, etc. was used.

AusführungsbeispielEmbodiment

Die Applikation erfolgt überlicherweise mittels einer kontinuierlichen intravenösen Infusion bei einer Dosierung von weniger als 10 ug/min da hierdurch die Bindungskinetik so eingestellt werden kann, daß bestehende Gerinnungsvorgänge in Wund- und Operationsgebieten minimal beeinflußt werden.The application is usually carried out by means of a continuous intravenous infusion at a Dosage of less than 10 µg / min since this enables the binding kinetics to be set in such a way that existing coagulation processes in wound and surgical areas are minimally influenced.

Wichtig ist darüber hinaus der Zeitpunkt der Anwendung.The time of application is also important.

Während einer gramnegativen Sepsis droht die oft letal verlaufende Komplikation einer disseminierten intravasalen Gerinnung (DIC). Die disseminierte intravasale Gerinnung ist eine Frühkomplikation der Sepsis, bei der in den kleinen Gefäßen des großen arteriellen Kreislaufs Mikrothromben entstehen. Bei diesen Patienten besteht eine Blutungstendenz als Folge des unkontrollierten Verbrauchs von Thrombozyten und Gerinnungsfaktoren. Durch Fibrinbildung in den Gefäßen kommt es zu Ischämie und einer daraus resultierenden Funktionsstörung der Organe. Die intravaskuläre Fibrinbildung kann zur Akkumulation von Leukozyten in den Lungen beitragen; Thrombin erhöht die Durchlässigkeit der Gefäße. Die sich entwickelnde DIC kann so zum auslösenden Faktor eines akuten Atemnotsyndroms werden.During gram-negative sepsis, the often lethal complication of disseminated threatens intravascular coagulation (DIC). Disseminated intravascular coagulation is an early complication of Sepsis, in which microthrombi develop in the small vessels of the large arterial circuit. At these patients have a tendency to bleed as a result of the uncontrolled consumption of Platelets and coagulation factors. Fibrin formation in the vessels leads to ischemia and a resulting malfunction of the organs. The intravascular fibrin formation can Contribute to the accumulation of leukocytes in the lungs; Thrombin increases the permeability of the Vessels. The developing DIC can thus trigger an acute respiratory distress syndrome become.

Obwohl eine Aktivierung der Neutrophilen nicht selbst den Gerinnungsprozeß auslöst, kann sie bei Patienten mit Sepsis Zytokine induzieren, so daß sich Mikrothromben bilden.Although neutrophil activation does not trigger the clotting process itself, it can help Patients with sepsis induce cytokines so that microthrombi form.

Wesentlich für den Zeitpunkt ist, daß mit der vorgeschlagenen Dosierung nicht bestehende Thrombozytenaggregationen aufgelöst, sondern lediglich die Bildung von neuen Thrombozytenaggregationen unterdrückt werden soll. Soweit die Thrombozytenaggregation bereits eingesetzt hat; wird diese abgeschwächt und im weiteren Verlauf unterdrückt.It is essential for the point in time that the proposed dosage does not exist Platelet aggregations dissolved, but only the formation of new ones Platelet aggregation should be suppressed. So much for platelet aggregation has started; this is weakened and suppressed in the further course.

Somit orientiert sich die vorgeschlagene Dosierung an den bekannten Werten, die bei nicht oder wenig aktivierten Thrombozyten ausreichen, um eine Thrombozytenaggregation zu unterdrücken, zumindest aber zu vermindern.Thus, the proposed dosage is based on the known values, the little or no activated platelets are sufficient to suppress platelet aggregation, at least but to diminish.

Es sind grundsätzlich 2 Vorgehensweisen möglich:
There are basically two approaches:

  • - eine prophylaktische Gabe von Abciximab unmittelbar nach der Diagnose einer Sepsis oder eines SIRS. Hierbei kann die vorgeschlagene Dosierung insbesondere dann auch unterschritten werden, wenn der Grad der Aktivierung der Thrombozyten und die Anzahl der freien Thrombozyten nicht wesentlich von ihren Normalwerten abweichen.- Prophylactic administration of abciximab immediately after diagnosis of sepsis or SIRS. In this case, the proposed dosage can also be fallen below, in particular if the degree of platelet activation and the number of free platelets is not differ significantly from their normal values.
  • - eine Gabe von Abciximab, sobald erkannt ist, daß die Aktivierung der Thrombozyten ansteigt und gleichzeitig die Anzahl der freien Thrombozyten sinkt. Hier ist die vorgeschlagene Dosierung als Dosierungsempfehlung anzusehen, der kurzfristig leicht überschritten werden kann, bis sich die genannten Werte, zumindest aber die Tendenz dieser Werte, stabilisiert haben.- Abciximab is administered as soon as it is recognized that platelet activation increases and at the same time the number of free platelets decreases. Here is the suggested dosage as  Dosage recommendation to look at, which can easily be exceeded in the short term until the mentioned values, or at least the tendency of these values, have stabilized.

Die vorgeschlagene Anwendung findet ihre Grenze dort, wo sich bei Patienten mit exzessivem Blutungsrisiko allgemein die Anwendung von Thrombozytenaggregationshemmern verbietet.The proposed application finds its limit where there is excessive use in patients Bleeding risk generally prohibits the use of platelet aggregation inhibitors.

Claims (1)

Verwendung von Abciximab zur Behandlung von Mikrozirkulationsstörungen in Folge von Sepsis oder SIRSUse of abciximab to treat microcirculatory disorders resulting from sepsis or SIRS
DE19753383A 1997-12-02 1997-12-02 Use of abciximab to treat microcirculation disorders Withdrawn DE19753383A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE19753383A DE19753383A1 (en) 1997-12-02 1997-12-02 Use of abciximab to treat microcirculation disorders
JP2000522947A JP2001524534A (en) 1997-12-02 1998-12-02 Use of a fibrinogen receptor antagonist to prevent disseminated intravascular coagulation
CA002312824A CA2312824A1 (en) 1997-12-02 1998-12-02 Use of a fibrinogen receptor-antagonist for preventing disseminated intravascular coagulation
EP98965225A EP1035868A1 (en) 1997-12-02 1998-12-02 Use of a fibrinogen receptor-antagonist for preventing disseminated intravascular coagulation
PCT/EP1998/007833 WO1999027962A1 (en) 1997-12-02 1998-12-02 Use of a fibrinogen receptor-antagonist for preventing disseminated intravascular coagulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19753383A DE19753383A1 (en) 1997-12-02 1997-12-02 Use of abciximab to treat microcirculation disorders

Publications (1)

Publication Number Publication Date
DE19753383A1 true DE19753383A1 (en) 1999-06-10

Family

ID=7850472

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19753383A Withdrawn DE19753383A1 (en) 1997-12-02 1997-12-02 Use of abciximab to treat microcirculation disorders

Country Status (5)

Country Link
EP (1) EP1035868A1 (en)
JP (1) JP2001524534A (en)
CA (1) CA2312824A1 (en)
DE (1) DE19753383A1 (en)
WO (1) WO1999027962A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2384196B1 (en) * 2008-12-30 2017-09-13 Johansson, Pär Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
CN114796215B (en) * 2022-05-27 2023-07-07 贵州医科大学 Application of tirofiban in preparing medicine for treating human respiratory syncytial virus infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795893A (en) * 1994-12-22 1998-08-18 Smithkline Beecham Corporation Fibrinogen receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICHTS ERMITTELT *

Also Published As

Publication number Publication date
JP2001524534A (en) 2001-12-04
EP1035868A1 (en) 2000-09-20
WO1999027962A1 (en) 1999-06-10
CA2312824A1 (en) 1999-06-10

Similar Documents

Publication Publication Date Title
DE60125541T2 (en) NEW NOT PSYCHOTROPIC CANNABINOIDS
DE4325927B4 (en) Medicament kit containing taxol
DE69534075T2 (en) PREVENTIVE AND CLEANING AGENTS FOR DISEASES CAUSED BY FIBRIN OR THROMBUS TRAINING
DE69839046T2 (en) USE OF A Factor a Inhibiting Oligosaccharide WITH A BLOOD CERTAIN AGENT FOR THE TREATMENT OF ARTERIENTHROMBOSES
DE60029340T2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A P2T RECEPTOR ANTAGONIST AND MELAGATRANE
DE69814444T2 (en) COMBINATION OF ANGIOTENSING-CONVERTIN ENZYME INHIBITORS WITH DIURETIC FOR TREATING MICROCIRCULATION DISORDERS
EP0328957B1 (en) Mixture of a thrombolytically acting and an antithrombolytically acting substance
DE69911633T2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING TETRAHYDROISOQUINOLINE COMPOUNDS
EP0087662A1 (en) Pharmaceuticals deposition system
DE2326600C2 (en)
DE2514335C3 (en) Oral drug with antiplasmin inhibitory effect
EP0312913B1 (en) Use of paf-antagonists for the preparation of a medicament and method for the determination of their binding-activity
EP0580685B1 (en) Pharmaceutical packaging unit containing plasminogen activators for multiple-bolus administration
DE19753383A1 (en) Use of abciximab to treat microcirculation disorders
DE4006564C2 (en) Use of hexadecylphosphocholine in the treatment of psoriasis
DE60120111T2 (en) USE OF AN EMAP-II RECEPTOR ANTAGONIST COMPOUND FOR THE TREATMENT OF PULMONARY HYPERTENSION
DE69535210T2 (en) Pharmaceutical composition containing 2,3-alkylcarbonyloxybenzoic acid and ibuprofen
DE60012183T2 (en) USE OF A MACROLIDE COMPOUND FOR PRODUCING A MEDICINE FOR TREATING BRAIN DAMAGE DUE TO ISCHEMIA OR BLEEDING
EP1605976B1 (en) PHENYLCARBOXYL ACID AMIDES AND IK r CHANNEL INHIBITORS COMBINATION AND THE USE THEREOF FOR TREATING ATRIAL ARRHYTHMIA
DE2145359A1 (en) New phthalate indenates
DE3426154A1 (en) USE OF N- (1-ALLYL-2-PYRROLIDINYLMETHYL) -2-METHOXY-4-AMINO-5-METHYLSULFAMOYL-BENZAMIDE
DE60004185T2 (en) SUPAR STIMULATING ACTIVITY ON TCUPA MEDIATED FIBRINOLYSIS AND VARIOUS USES THEREOF
DE2760410C2 (en)
DE19622866C2 (en) Use of preparations containing opiate antagonists and agonists for the prophylaxis and therapeutic treatment of migraines and migraine-related diseases
DE60019166T2 (en) USE OF ADATANSERIN FOR THE TREATMENT OF ACUTE NEURODEGENERATIVE DISEASES

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8127 New person/name/address of the applicant

Owner name: WIEMANN, GUNDULA, 70190 STUTTGART, DE

8127 New person/name/address of the applicant

Owner name: WIEMANN, GUNDULA, 45279 ESSEN, DE

8139 Disposal/non-payment of the annual fee